Gracell Biotechnologies Balans Gezondheid

Financiële gezondheid criteriumcontroles 5/6

Gracell Biotechnologies heeft een totaal eigen vermogen van CN¥1.6B en een totale schuld van CN¥103.1M, wat de schuld-eigenvermogensverhouding op 6.4% brengt. De totale activa en totale passiva bedragen respectievelijk CN¥1.9B en CN¥268.9M.

Belangrijke informatie

6.4%

Verhouding schuld/eigen vermogen

CN¥103.15m

Schuld

Rente dekkingsratio	n/a
Contant	CN¥1.71b
Aandelen	CN¥1.62b
Totaal verplichtingen	CN¥268.86m
Totaal activa	CN¥1.89b

Recente financiële gezondheidsupdates

Recent updates

AstraZeneca Deal For Gracell Biotechnologies Closing Tomorrow (Includes CVR)

Feb 21

Gracell Biotechnologies initiated at buy at Citi citing its autologous CAR-T platform

Sep 22

Gracell Bio Shares Tumble As Investors Blow Hot, Cold Over Its Cutting-Edge Cancer Treatment

Nov 26

Gracell ends IPO quiet period with favorable views from analysts

Feb 02

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( CN¥1.8B ) GRCL } overtreffen de korte termijn passiva ( CN¥229.5M ).

Langlopende schulden: De kortetermijnactiva GRCL ( CN¥1.8B ) overtreffen de langetermijnschulden ( CN¥39.4M ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: GRCL heeft meer geld in kas dan de totale schuld.

Schuld verminderen: Er zijn onvoldoende gegevens om te bepalen of de schuld/eigen vermogen-ratio van GRCL de afgelopen 5 jaar is gedaald.

Balans

Analyse van de cashflow

Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.

Stabiele cash runway: GRCL heeft op basis van de huidige vrije kasstroom voldoende kasstroom voor meer dan een jaar.

Voorspelling contante baan: GRCL heeft voldoende kasruimte voor 2.7 jaar als de vrije kasstroom blijft dalen met een historisch percentage van 33.3 % per jaar.

Gracell Biotechnologies Balans Gezondheid

Financiële gezondheid criteriumcontroles 5/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Gracell Biotechnologies Files Form 15

Recent updates

Gracell Biotechnologies Files Form 15

AstraZeneca Treasury Limited completed the acquisition of Gracell Biotechnologies Inc. (NasdaqGS:GRCL) from a group of shareholders.

Gracell Biotechnologies Inc.(NasdaqGS:GRCL) dropped from NASDAQ Composite Index

AstraZeneca Treasury Limited completed the acquisition of Gracell Biotechnologies Inc. (NasdaqGS:GRCL) from a group of shareholders.

AstraZeneca Deal For Gracell Biotechnologies Closing Tomorrow (Includes CVR)

Price target decreased by 9.7% to US$10.58

Gracell Biotechnologies Announces China NMPA Clearance for IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Refractory Systemic Lupus Erythematosus

Gracell Biotechnologies Inc. Presents Updated Clinical Data from FasTCAR-T GC012F Demonstrating Deep and Durable Responses in Newly Diagnosed Multiple Myeloma At ASH 2023

Gracell Biotechnologies Presents Updated Clinical Data from FasTCAR-T GC012F Demonstrating Deep and Durable Responses in Newly Diagnosed Multiple Myeloma at ASH 2023

Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Refractory Systemic Lupus Erythematosus

Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Refractory Systemic Lupus Erythematosus

Founder notifies of intention to sell stock

New major risk - Revenue and earnings growth

Price target decreased by 11% to US$11.43

Gracell Biotechnologies to Present Updated Results from BCMA/CD19 Dual-Targeting FasTCAR-T GC012F in Newly Diagnosed Multiple Myeloma at the 65h American Society of Hematology Annual Meeting & Exposition

Gracell Biotechnologies Inc. to Present Data Highlighting Preclinical Efficacy of Smart Cart Against Solid Tumors At Society for Immunotherapy of Cancer 38th Annual Meeting

Gracell Biotechnologies Inc. to Report Q3, 2023 Results on Nov 13, 2023

Gracell Biotechnologies Reports Updated Clinical Data for Fastcar-T Gc012f for High-Risk, Newly Diagnosed Multiple Myeloma, Demonstrating 100% Stringent Complete Response Rate

Gracell Biotechnologies Doses First Patient in Phase 1B/2 Clinical Trial in U.S. Evaluating GC012F for Treatment of Relapsed/Refractory Multiple Myeloma

Founder notifies of intention to sell stock

New minor risk - Shareholder dilution

Gracell Biotechnologies Inc. announced that it expects to receive $150.008003 million in funding from a group of investors

Gracell Biotechnologies Inc. announced that it expects to receive $150.008003 million in funding from a group of investors

Gracell Biotechnologies Inc. to Report Q2, 2023 Results on Aug 14, 2023

Founder notifies of intention to sell stock

Gracell Biotechnologies Inc. Presents Longer-Term Results for FasTCAR-T GC012F in B-Cell Non-Hodgkin’s Lymphoma at EHA2023, Highlighting 100% Overall Response Rate

Gracell Biotechnologies Inc., Annual General Meeting, Jul 13, 2023

Gracell Biotechnologies Inc. Initiates Investigational Study Evaluating Gc012f for Treatment of Refractory Systemic Lupus Erythematosus

Founder notifies of intention to sell stock

Price target decreased by 12% to US$12.57

Gracell Biotechnologies Announces China NMPA Clearance for IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for Treatment of Relapsed/Refractory Multiple Myeloma

Gracell Biotechnologies Inc. Announces FDA Clearance of the IND Application for Phase 1b/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Relapsed/Refractory Multiple Myeloma

Gracell Biotechnologies Inc. Presents Clinical Data for FasTCAR-T GC012F for High Risk, Newly Diagnosed Multiple Myeloma Demonstrating 100% Overall Response Rate

Founder notifies of intention to sell stock

Less than half of directors are independent

Founder notifies of intention to sell stock

Gracell Biotechnologies Inc. to Report Q3, 2022 Results on Nov 14, 2022

Gracell Biotechnologies Doses First Patient in Phase 2 Portion of Registrational Phase 1/2 Clinical Trial Evaluating GC007g for Treatment of B-Cell Acute Lymphoblastic Leukemia

Gracell Biotechnologies initiated at buy at Citi citing its autologous CAR-T platform

Gracell Biotechnologies GAAP EPS of -$0.06 beats by $0.02

Gracell Biotechnologies Inc. to Report Q2, 2022 Results on Aug 15, 2022

Gracell Biotechnologies Inc. Appoints Dr. Wendy Li as Chief Medical Officer

Gracell Biotechnologies rallies after naming new chief medical officer

Gracell Biotechnologies Inc. Appoints Veteran Biopharma Executive Dr. Samuel Zhang as Chief Business Officer

Gracell names Dr. Samuel Zhang as Chief Business Officer

Chief Medical Officer notifies of intention to sell stock

Gracell Biotechnologies Presents Updated Clinical Data for BCMA/CD19 Dual-Targeting FasTCAR GC012F in RRMM at EHA2022 Congress

Gracell Biotechnologies Inc. to Present Updated Clinical Data on BCMA/CD19 Dual-Targeting Car-T GC012f for Relapsed/Refractory Multiple Myeloma At 2022 ASCO Annual Meeting

Price target decreased to US$19.00

Gracell Biotechnologies Inc. to Report Q1, 2022 Results on May 16, 2022

Less than half of directors are independent

Gracell Biotechnologies Inc. Announces Early Results of First-In-Human Clinical Study of GC502 for Treatment of Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Price target decreased to US$28.33

Gracell Biotechnologies Inc. to Report Q4, 2021 Results on Mar 14, 2022

Gracell Biotechnologies Inc. Announces Multiple Advancements of TruUCAR Allogeneic CAR-T Platform

Gracell Biotechnologies Inc. Doses First Patients in First-In-Human Clinical Trial Evaluating GC012F, its Dual-Targeting FasTCAR-T Therapy, in B-Cell Non-Hodgkin's Lymphoma

Chief Medical Officer notifies of intention to sell stock

Gracell Bio Shares Tumble As Investors Blow Hot, Cold Over Its Cutting-Edge Cancer Treatment

Forecast to breakeven in 2025

Gracell Biotechnologies Inc. to Present Updated Results of Gc012f Fastcar-Enabled Bcma/Cd19 Dual-Targeting Car-T Cell Therapy for Relapsed/Refractory Multiple Myeloma At Asco 2021 and Eha 2021

Gracell Biotechnologies Inc. to Report Q4, 2020 Results on Mar 09, 2021

Gracell ends IPO quiet period with favorable views from analysts

Gracell Biotechnologies Inc. Receives IND Approval from China NMPA for GC019F

Gracell Biotechnologies Receives Medical Products Manufacturing Certificate for CAR-T Cell Therapy Products

China NMPA Grants Approval to Gracell Biotechnologies Inc. for Registrational Phase 1/2 Clinical Study for GC007g - an Allogeneic CAR-T Cell Therapy for Treatment of Relapsed or Refractory B-ALL

Gracell Biotechnologies Inc. has completed an IPO in the amount of $209 million.

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans

Analyse van de cashflow

Ontdek gezonde bedrijven